West Pharmaceutical Services (WST) Stock Forecast & Price Target

Compare

868 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WST Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

West

Pharmaceutical Services

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WST Stock 12 Month Forecast

Average Price Target

$348.70

▲(27.12% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $348.70 with a high forecast of $375.00 and a low forecast of $285.00. The average price target represents a 27.12% change from the last price of $274.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"208":"$208","250":"$250","292":"$292","334":"$334","376":"$376"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$375.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":348.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$348.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$285.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[208,250,292,334,376],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,274.14,281.8984615384615,289.6569230769231,297.4153846153846,305.17384615384617,312.9323076923077,320.6907692307692,328.4492307692308,336.2076923076923,343.9661538461538,351.7246153846154,359.4830769230769,367.2415384615385,{"y":375,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,274.14,279.8753846153846,285.6107692307692,291.3461538461538,297.08153846153846,302.81692307692305,308.5523076923077,314.2876923076923,320.0230769230769,325.7584615384615,331.49384615384616,337.22923076923075,342.9646153846154,{"y":348.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,274.14,274.9753846153846,275.8107692307692,276.6461538461538,277.48153846153843,278.31692307692305,279.15230769230766,279.9876923076923,280.82307692307694,281.65846153846155,282.49384615384616,283.3292307692308,284.1646153846154,{"y":285,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":321.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":340.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":274.14,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$375.00

Average Price Target$348.70

Lowest Price Target$285.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Ryskin

Bank of America Securities

$370

Buy

34.89%

Upside

Reiterated

12/15/25

Bank of America Securities Remains a Buy on West Pharmaceutical Services (WST)

Luke Sergott

Barclays

$325

Hold

18.48%

Upside

Reiterated

12/15/25

West Pharmaceutical Services (WST) Gets a Hold from Barclays

Thomas DeBourcy

Nephron

$367

Buy

33.80%

Upside

Upgraded

12/11/25

West Pharmaceutical upgraded to Buy from Hold at Nephron ResearchWest Pharmaceutical upgraded to Buy from Hold at Nephron Research

Brendan Smith

TD Cowen

$350

Buy

27.60%

Upside

Reiterated

12/09/25

since our initiation last month (see our note Initiating With Buy: The Era Of Injectables Leads All RoadsWest) with Price Target: $350.00

Kallum Titchmarsh

Morgan Stanley

$285

Hold

3.90%

Upside

Initiated

12/02/25

West Pharmaceutical initiated with an Equal Weight at Morgan StanleyWest Pharmaceutical initiated with an Equal Weight at Morgan Stanley

David Windley

Jefferies

$365

Buy

33.07%

Upside

Reiterated

11/19/25

Jefferies Remains a Buy on West Pharmaceutical Services (WST)

Daniel Markowitz CFA

Evercore ISI

Buy

―

Reiterated

10/27/25

West Pharmaceutical removed from 'Tactical Outperform' list at Evercore ISIWest Pharmaceutical removed from 'Tactical Outperform' list at Evercore ISI

Dan Leonard

UBS

$320→$355

Buy

29.42%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $355 from $320 at UBSWest Pharmaceutical price target raised to $355 from $320 at UBS

Patrick B Donnelly

Citi

$350→$375

Buy

36.71%

Upside

Reiterated

10/24/25

West Pharmaceutical Services (WST) Receives a Buy from Citi

Paul Knight

KeyBanc

$325→$350

Buy

27.60%

Upside

Reiterated

10/24/25

KeyBanc Keeps Their Buy Rating on West Pharmaceutical Services (WST)

Justin Bowers

Deutsche Bank

$305→$345

Buy

25.77%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $345 from $305 at Deutsche BankWest Pharmaceutical price target raised to $345 from $305 at Deutsche Bank

Matt Larew

William Blair

Buy

―

Reiterated

10/23/25

Strong Q3 Performance and Raised 2025 Guidance Justify Buy Rating for West Pharmaceutical Services

Jamie Clark

Rothschild & Co Redburn

$311

Buy

13.38%

Upside

Initiated

09/15/25

West Pharmaceutical Services (WST) Has a New Rating from Redburn Atlantic

Nico Chen

DBS

$265

Buy

-3.39%

Downside

Reiterated

06/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (NYSE: WST), Blueprint Medicines (NASDAQ: BPMC) and Vera Therapeutics (NASDAQ: VERA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Ryskin

Bank of America Securities

$370

Buy

34.89%

Upside

Reiterated

12/15/25

Bank of America Securities Remains a Buy on West Pharmaceutical Services (WST)

Luke Sergott

Barclays

$325

Hold

18.48%

Upside

Reiterated

12/15/25

West Pharmaceutical Services (WST) Gets a Hold from Barclays

Thomas DeBourcy

Nephron

$367

Buy

33.80%

Upside

Upgraded

12/11/25

West Pharmaceutical upgraded to Buy from Hold at Nephron ResearchWest Pharmaceutical upgraded to Buy from Hold at Nephron Research

Brendan Smith

TD Cowen

$350

Buy

27.60%

Upside

Reiterated

12/09/25

since our initiation last month (see our note Initiating With Buy: The Era Of Injectables Leads All RoadsWest) with Price Target: $350.00

Kallum Titchmarsh

Morgan Stanley

$285

Hold

3.90%

Upside

Initiated

12/02/25

West Pharmaceutical initiated with an Equal Weight at Morgan StanleyWest Pharmaceutical initiated with an Equal Weight at Morgan Stanley

David Windley

Jefferies

$365

Buy

33.07%

Upside

Reiterated

11/19/25

Jefferies Remains a Buy on West Pharmaceutical Services (WST)

Daniel Markowitz CFA

Evercore ISI

Buy

―

Reiterated

10/27/25

West Pharmaceutical removed from 'Tactical Outperform' list at Evercore ISIWest Pharmaceutical removed from 'Tactical Outperform' list at Evercore ISI

Dan Leonard

UBS

$320→$355

Buy

29.42%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $355 from $320 at UBSWest Pharmaceutical price target raised to $355 from $320 at UBS

Patrick B Donnelly

Citi

$350→$375

Buy

36.71%

Upside

Reiterated

10/24/25

West Pharmaceutical Services (WST) Receives a Buy from Citi

Paul Knight

KeyBanc

$325→$350

Buy

27.60%

Upside

Reiterated

10/24/25

KeyBanc Keeps Their Buy Rating on West Pharmaceutical Services (WST)

Justin Bowers

Deutsche Bank

$305→$345

Buy

25.77%

Upside

Reiterated

10/24/25

West Pharmaceutical price target raised to $345 from $305 at Deutsche BankWest Pharmaceutical price target raised to $345 from $305 at Deutsche Bank

Matt Larew

William Blair

Buy

―

Reiterated

10/23/25

Strong Q3 Performance and Raised 2025 Guidance Justify Buy Rating for West Pharmaceutical Services

Jamie Clark

Rothschild & Co Redburn

$311

Buy

13.38%

Upside

Initiated

09/15/25

West Pharmaceutical Services (WST) Has a New Rating from Redburn Atlantic

Nico Chen

DBS

$265

Buy

-3.39%

Downside

Reiterated

06/03/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (NYSE: WST), Blueprint Medicines (NASDAQ: BPMC) and Vera Therapeutics (NASDAQ: VERA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering West Pharmaceutical Services

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

+2.82%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +2.82% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+6.62%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +6.62% per trade.

1 Year

Paul KnightKeyBanc

Success Rate

10/14 ratings generated profit

Average Return

+12.92%

reiterated a buy rating 2 months ago

Copying Paul Knight's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +12.92% per trade.

2 Years

xxx

Success Rate

9/14 ratings generated profit

Average Return

+18.59%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +18.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WST Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WST has received 17 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. WST average Analyst price target in the past 3 months is 348.70.

Each month's total comprises the sum of three months' worth of ratings.

WST Financial Forecast

WST Earnings Forecast

Next quarter’s earnings estimate for WST is $1.83 with a range of $1.80 to $1.88. The previous quarter’s EPS was $1.96. WST beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year WST has Performed in-line its overall industry.

WST Sales Forecast

Next quarter’s sales forecast for WST is $795.90M with a range of $790.39M to $801.80M. The previous quarter’s sales results were $804.30M. WST beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year WST has Performed in-line its overall industry.

WST Stock Forecast FAQ

What is WST’s average 12-month price target, according to analysts?

Based on analyst ratings, West Pharmaceutical Services, Inc.’s 12-month average price target is 348.70.

What is WST’s upside potential, based on the analysts’ average price target?

West Pharmaceutical Services, Inc. has 27.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WST a Buy, Sell or Hold?

West Pharmaceutical Services, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is West Pharmaceutical Services, Inc.’s price target?

The average price target for West Pharmaceutical Services, Inc. is 348.70. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $375.00 ,the lowest forecast is $285.00. The average price target represents 27.12% Increase from the current price of $274.3.

What do analysts say about West Pharmaceutical Services, Inc.?

West Pharmaceutical Services, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of WST?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

West Pharmaceutical Services (WST) Stock Forecast & Price Target

WST Analyst Ratings

WST Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering West Pharmaceutical Services

WST Analyst Recommendation Trends

WST Financial Forecast

WST Earnings Forecast

WST Sales Forecast

WST Stock Forecast FAQ

Detailed List of Analyst Forecasts